Of Interest

Anti–LAG-3/Anti–PD-1 Combo Demonstrates Sustained Efficacy in Melanoma

Meredith McKean, MD, MPH, director of melanoma and skin cancer research at Sarah Cannon Research Institute, discusses the background and goals from the recent long-term follow-up of a phase 1 study (NCT03005782) evaluating the combination of fianlimab, an anti–LAG-3 agent, and cemiplimab (Libtayo), an anti–PD-1 agent, in patients with advanced melanoma.

Read More
MRV News
Melanoma News
Archive
Menu